MX2014011828A - Anticuerpo anti-siglec-15 con region determinante de complementariedad modificada. - Google Patents

Anticuerpo anti-siglec-15 con region determinante de complementariedad modificada.

Info

Publication number
MX2014011828A
MX2014011828A MX2014011828A MX2014011828A MX2014011828A MX 2014011828 A MX2014011828 A MX 2014011828A MX 2014011828 A MX2014011828 A MX 2014011828A MX 2014011828 A MX2014011828 A MX 2014011828A MX 2014011828 A MX2014011828 A MX 2014011828A
Authority
MX
Mexico
Prior art keywords
antibody
siglec15
modified cdr
osteoclasts
pharmaceutical composition
Prior art date
Application number
MX2014011828A
Other languages
English (en)
Inventor
Yoshiharu Hiruma
Takako Kimura
Hironari Shimizu
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MX2014011828A publication Critical patent/MX2014011828A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se provee una composición farmacéutica para el tratamiento y/o profilaxis del metabolismo óseo anormal que hace blanco en una proteína codificada por un gen expresado fuertemente en osteoclastos; específicamente, se provee una composición farmacéutica que contiene un anticuerpo que reconoce específicamente a Siglec-15 de humano y tiene actividad de inhibición de la formación de osteoclastos, y similares.
MX2014011828A 2012-03-30 2013-03-29 Anticuerpo anti-siglec-15 con region determinante de complementariedad modificada. MX2014011828A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012078842 2012-03-30
PCT/JP2013/059654 WO2013147213A1 (ja) 2012-03-30 2013-03-29 ＣＤＲ改変抗Ｓｉｇｌｅｃ－１５抗体

Publications (1)

Publication Number Publication Date
MX2014011828A true MX2014011828A (es) 2014-12-10

Family

ID=49260454

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011828A MX2014011828A (es) 2012-03-30 2013-03-29 Anticuerpo anti-siglec-15 con region determinante de complementariedad modificada.

Country Status (20)

Country Link
US (1) US9464133B2 (es)
EP (1) EP2832857B1 (es)
JP (1) JP6059205B2 (es)
KR (1) KR20150003170A (es)
CN (1) CN104334722A (es)
AU (1) AU2013241003A1 (es)
BR (1) BR112014024269A8 (es)
CA (1) CA2868959A1 (es)
ES (1) ES2660472T3 (es)
HK (1) HK1204657A1 (es)
IL (1) IL234883A0 (es)
IN (1) IN2014DN08215A (es)
MX (1) MX2014011828A (es)
NZ (1) NZ631509A (es)
PH (1) PH12014502187A1 (es)
RU (1) RU2014143798A (es)
SG (1) SG11201405966PA (es)
TW (1) TW201343672A (es)
WO (1) WO2013147213A1 (es)
ZA (1) ZA201407079B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
SI2206727T1 (sl) 2007-10-11 2015-06-30 Daiichi Sankyo Company, Limited Protitelo, ki cilja osteoklast - soroden protein Siglec-15
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
JP2017523148A (ja) * 2014-06-18 2017-08-17 第一三共株式会社 骨形成不全症の治療に使用するための抗Ｓｉｇｌｅｃ−１５抗体
CN110268268A (zh) * 2017-02-03 2019-09-20 住友化学株式会社 胰腺癌的检查方法
EP3646885A4 (en) * 2017-06-30 2021-04-28 National University Corporation Hokkaido University MEDICINAL PRODUCTS AGAINST OSTEOPOROSIS IN CHILDREN WITHOUT CAUSING GROWTH DISORDERS
CN113817057B (zh) * 2020-06-19 2024-02-20 盛禾(中国)生物制药有限公司 一种抗siglec15抗体及其应用
WO2022179483A1 (zh) * 2021-02-23 2022-09-01 上海济煜医药科技有限公司 Siglec-15结合蛋白的制备及其用途
CN114957468A (zh) * 2021-02-25 2022-08-30 石药集团巨石生物制药有限公司 一种抗Siglec15抗体及其用途
CN113577283A (zh) * 2021-07-19 2021-11-02 河北医科大学第三医院 Siglec-15抑制剂在制备防治骨巨细胞瘤药物中的应用
WO2023030311A1 (zh) * 2021-08-31 2023-03-09 上海医药集团股份有限公司 靶向Siglec15的抗原结合蛋白及其用途
WO2023241538A1 (en) * 2022-06-13 2023-12-21 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-siglec15 antibodies and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
EP0911342B2 (en) 1997-04-15 2013-05-22 Daiichi Sankyo Company, Limited Novel protein and process for producing the same
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
DK2270150T4 (da) 1999-04-09 2019-08-26 Kyowa Hakko Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle.
EP2314686B2 (en) 2000-10-06 2023-06-21 Kyowa Kirin Co., Ltd. Cells producing antibody compositions
US20040082508A1 (en) 2000-11-08 2004-04-29 Henry Yue Secreted proteins
US7608704B2 (en) 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
WO2002064771A1 (fr) 2001-02-15 2002-08-22 Mochida Pharmaceutical Co., Ltd. Nouvelle molecule d'adhesion cellulaire specifique de leucocyte active
DK2295081T3 (en) 2001-06-26 2019-02-18 Amgen Inc Antibodies to OPGL
EP1456655A2 (en) 2001-11-13 2004-09-15 Incyte Genomics, Inc. Receptors and membrane-associated proteins
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
WO2004061104A2 (en) 2003-01-07 2004-07-22 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
US7405037B2 (en) 2004-05-07 2008-07-29 Lonza Walkersville, Inc. Methods and tools for detecting collagen degradation
JP4604184B2 (ja) 2005-07-12 2010-12-22 独立行政法人産業技術総合研究所 新規糖鎖認識蛋白質及びその遺伝子
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US7989160B2 (en) 2006-02-13 2011-08-02 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
SI2206727T1 (sl) * 2007-10-11 2015-06-30 Daiichi Sankyo Company, Limited Protitelo, ki cilja osteoklast - soroden protein Siglec-15
CN106317224B (zh) * 2009-04-09 2020-05-12 第一三共株式会社 抗-Siglec-15抗体
CN103237813A (zh) 2010-10-05 2013-08-07 第一三共株式会社 靶向破骨细胞相关蛋白涎免凝集素-15的抗体

Also Published As

Publication number Publication date
IL234883A0 (en) 2014-12-31
US9464133B2 (en) 2016-10-11
PH12014502187A1 (en) 2014-12-10
TW201343672A (zh) 2013-11-01
EP2832857A4 (en) 2016-02-17
AU2013241003A1 (en) 2014-10-16
EP2832857A1 (en) 2015-02-04
EP2832857B1 (en) 2018-01-03
KR20150003170A (ko) 2015-01-08
US20150056189A1 (en) 2015-02-26
WO2013147213A1 (ja) 2013-10-03
NZ631509A (en) 2016-09-30
BR112014024269A2 (es) 2017-06-20
JPWO2013147213A1 (ja) 2015-12-14
CN104334722A (zh) 2015-02-04
CA2868959A1 (en) 2013-10-03
RU2014143798A (ru) 2016-05-27
ES2660472T3 (es) 2018-03-22
JP6059205B2 (ja) 2017-01-11
HK1204657A1 (en) 2015-11-27
SG11201405966PA (en) 2014-11-27
IN2014DN08215A (es) 2015-05-15
BR112014024269A8 (pt) 2017-07-25
ZA201407079B (en) 2016-02-24

Similar Documents

Publication Publication Date Title
MX2014011828A (es) Anticuerpo anti-siglec-15 con region determinante de complementariedad modificada.
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
PH12014501595A1 (en) Substituted annulated pyrimidines and triazines, and use thereof
MX2019013123A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
MX2015007921A (es) Compuestos heterociclicos novedosos como inhibidores de bromodominio.
GB201106743D0 (en) Novel compounds
MX337577B (es) Anticuerpos c-kit y usos de los mismos.
MX2013008547A (es) Composicion efervescente en forma solida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales.
MX348470B (es) Pirimidinas anilladas sustituidas y uso de las mismas.
MX366130B (es) Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos.
MX2015005963A (es) Inhibidores heterociclicos de glutaminasa.
GB201106750D0 (en) Novel compounds
BR112014024267A8 (pt) anticorpo ou um fragmento de ligação de antígeno do anticorpo, composição farmacêutica, usos de pelo menos um dos anticorpos ou fragmentos de ligação de antígeno e de uma composição, polinucleotídeo, vetor, e, célula hospedeira transformada
UY34558A (es) Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
PH12014502496B1 (en) Bicyclically substituted uracils and the use thereof
MX2015002669A (es) Metodos de administracion de tratamiento con pirfenidona.
AU341611S (en) Dual function wine system
CA2905610C (en) Hyaluronic acid derivatives
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
GB201109238D0 (en) Antibodies
MX2015008877A (es) Conjugados de disulfuro mixto de compuestos de tienopiridina y sus usos.
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
IN2014DN08385A (es)
UA112760C2 (uk) Теобромін у комбінації з гвайфенезином для лікування кашлю
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine